Who is sponsoring NCT06362291?

NCT06362291 is sponsored by Peking University First Hospital.

What drugs are being tested in NCT06362291?

Interventions in NCT06362291: MRI-AI guided cognitive prostate targeted biopsy, Routine cognitive prostate targeted biopsy.

What condition does NCT06362291 study?

NCT06362291 studies Prostate Cancer.

Is NCT06362291 still recruiting?

NCT06362291 is currently completed. Last updated 20 November 2024.

Last reviewed 2024-11-20 · How we verify

NCT06362291

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of MRI AI-cTB Versus Routine cTB in Prostate Cancer Diagnosis: a Prospective Randomized Controlled Trial

Completed NA Last updated 20 November 2024

What this trial tests

NA trial testing MRI-AI guided cognitive prostate targeted biopsy in Prostate Cancer in 380 participants. Completed in 31 October 2024.

Timeline

1 August 2023

Primary endpoint
31 March 2024

31 October 2024

Quick facts

Lead sponsor	Peking University First Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	diagnostic
Enrollment	380
Start date	1 August 2023
Primary completion	31 March 2024
Estimated completion	31 October 2024
Sites	1 location across China

Drugs / interventions tested

MRI-AI guided cognitive prostate targeted biopsy
Routine cognitive prostate targeted biopsy

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Peking University First Hospital

Who can join

Adults 45 to 85, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical trial is to compare the cancer detection rates of MRI artificial intelligence-guided cTB (AI-cTB) and routine cTB, and explore the added value of using AI for the guidance of cTB. The main questions it aims to answer are: Does AI-cTB promote the accurate diagnosis and treatment of prostate cancer? What's the value of prostate MRI artificial intelligence assistant diagnosis system in developing the best scheme of prostate biopsy? What's the value of prostate MRI artificial intelligence assistant diagnosis system in predicting the pathological results of prostate targeted biopsy? Researchers will compare the cancer detection rates of AI-cTB and routine cTB to explore the added value of using AI for the guidance of cTB. Participants will: Receive AI-cTB or routine cTB.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Comparison of MRI artificial intelligence-guided cognitive fusion-targeted biopsy versus routine cognitive fusion-targeted prostate biopsy in prostate cancer diagnosis: a randomized controlled trial.
Deng R, Liu Y, Wang K, Ruan M, et al · · 2024 · cited 11× · PMID 39533250 · DOI 10.1186/s12916-024-03742-z
Artificial Intelligence for the Diagnosis and Management of Cancers: Potentials and Challenges.
Wang M, Chang W, Zhang Y. · · 2025 · cited 1× · PMID 41200279 · DOI 10.1002/mco2.70460

Verify or expand the search:

Other trials of MRI-AI guided cognitive prostate targeted biopsy

Trials testing the same drug.

NCT06392737 — Comparison of MRI Artificial Intelligence-guided cTB Versus Routine cTB in Prostate Cancer Diagnosis · NA · recruiting

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Peking University First Hospital trials

Trials by the same sponsor.

NCT07498907 — Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelia · Phase 2 · not yet recruiting
NCT07517276 — TUDCA in High-Risk Lactating Mothers Identified by Early Postpartum Milk Hydrophobicity Index · Phase 2 · not yet recruiting
NCT07504939 — Multimodal Kidney-Sparing Strategy for High-Risk Upper Tract Urothelial Carcinoma · not yet recruiting
NCT07464119 — A Clinical Study of iPSC-Derived Islet Cells for Diabetes Mellitus Therapy · NA · not yet recruiting
NCT07460843 — Comparison of TB+PB and TB+6SB for Prostate Cancer Diagnosis · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06362291 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking University First Hospital
Last refreshed: 20 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06362291.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing